NCT07768267
Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel Syndrome
At risk: Primary completion moved 12 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 6 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial status changed: Enrolling by Invitation → Recruiting
- Site details revised
- Notable Enrolling by invitation only
- Start date changed from estimate of Nov 1, 2026 to Oct 26, 2026
- Site contact updated
- Notable Start date pushed from Oct 1, 2026 to Nov 1, 2026
- Eligibility criteria expanded, about 20 words
- Secondary endpoints: details revised at 3 of 3 entries
- Publications: details revised at 1 of 1 entry
- Notable Primary and study completion dates pushed to Dec 31, 2027
- Start date: Sep 1, 2026 to Oct 1, 2026
- Minor Site contact updatedv3
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
Participants receive Biocidin REMOVE capsules, a herbal preparation supplied as a 665 mg capsule containing 325 mg of the active proprietary blend. Dosing begins with a 9-day titration, increasing by one capsule every three days: one capsule once daily on Days -9 to -7, one capsule twice daily on Days -6 to -4, and two capsules in the morning with one in the evening on Days -3 to -1. Participants reach the target dose of two capsules twice daily on Day 1 and continue at that dose through Day 28. Capsules are identical in appearance to placebo.
Participants receive matching placebo capsules, identical in appearance to Biocidin REMOVE and containing no active ingredients. Placebo follows the same 9-day titration and dosing schedule as the experimental arm: one capsule once daily on Days -9 to -7, one capsule twice daily on Days -6 to -4, two capsules in the morning with one in the evening on Days -3 to -1, then two capsules twice daily on Days 1 through 28.
Drugs: Biocidin REMOVE, Placebo
Sites
1 site in 1 country
- Johns Hopkins HospitalBaltimore, Maryland, United States